Poor Merck KGaA. Shares have fallen more than 5% in the wake of the sudden and unexpected Bernhard Scheuble's departure of CEO Bernhard Scheuble from the firm.
The whispers are that Dr Scheuble may have had a disagreement with the Merck family over the firm's future strategy.
The Merck family hold a controlling 73% stake in the business, most widely known for its treatments for cancer, heart disease and diabetes.
The reins are being picked up by vice-chairman Michael Roemer.
Insider wonders what the "differences in strategy" might have been? Other family owned firms are up for sale at the moment (Serono, for example).
Time will tell, no doubt.
No comments:
Post a Comment